Women in Ophthalmology - 10 Minutes of Science Women in Ophthalmology

 Impressed with a 50% success rate?
Witnessing blinding acute angle attacks motivated Dr Judy Ku’s passion for primary angle closure disease. She explores how a 50% success rate sounds impressive, but its real-world outcomes are less, especially when factoring in the economic costs of large population screening and proactive treatment. So, while laser peripheral iridotomy is effective in reducing the risk progression to primary angle closure and acute angle closure attacks – what are the caveats? Listen in to find out.

View Article here

Superiority complex? It is complex
Associate Professor Susan Carden examines the RAINBOW study, which compared treatment of ROP with ranibizumab versus laser therapy. Noting the extension trial may uncover more, there might be a superior treatment method. Listen in to find out more.
View article here 
Susan Carden is an Associate Professor in the Department of Pediatrics, University of Melbourne.  She is a Consultant Ophthalmologist RCH and is head of the Education Vision Assessment Unit, RVEEH. She currently chairs the Victorian Branch, RANZCO.  Her areas of 
expertise includes retinopathy of prematurity, Low Vision, paediatric ophthalmology and general ophthalmology and international development.

For Fuchs’s sake, taking out the sting
Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs’ Endothelial Dystrophy
Professor Stephanie Watson talks taking the sting out of Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs’ Endothelial Dystrophy. Do the clinical outcomes support their use, and how robust was this Double-Masked, Randomized Controlled Trial?
View article here
Stephanie Watson is the Head of the Corneal Research Group at the Save Sight Institute at the University of Sydney. She is the co-Deputy Director of Industry, Innovation and Commercialisation at Sydney Nano, the Head of the Corneal Unit at Sydney Eye Hospital and Chair of Australian Vision Research (formerly Ophthalmic Research Institute of Australia).

Talking “pulleyes”… and when they no longer hold tension 
When a trans-pacific collaboration results in need-to-know outcomes for the general ophthalmologist. The differences in patterns of sagging eye syndrome lead to different treatment paths. Dr Sonia Moorthy unpacks diagnosis, simple and effective management strategies and ways to reduce unnecessary investigations. 
View article here
Sonia Moorthy is an adult and paediatric ophthalmologist with fellowships in paediatric ophthalmology and strabismus, at the prestigious Singapore National Eye Centre and Moorfields Eye Hospital, London. She has a Master of Public Health at the University of Melbourne and has a strong interest in indigenous health. She has volunteered as a field researcher in the Pilbara, WA as part of the National Indigenous Eye Survey and has been providing adult and paediatric eye care in Far North Queensland, privately and publicly. In particular, she has gained extensive experience in Indigenous eye care, serving communities up to Cape York. 

Rebounds are not limited to basketball.  Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout. 
Rebounds are not limited to basketball. Dr Sarah Hull examines the rebound effect in the Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study. What are the outcomes of continued atropine treatment, and what is the ideal concentration? 
View article here
Sarah Hull is a UK-trained Ophthalmologist who completed a PhD in paediatric retinal genetics at UCL and Moorfields in 2016. She has been living in New Zealand since 2018, working as a consultant Ophthalmologist specialising in paediatrics, strabismus and genetics at Auckland District Health Board and Auckland Eye. She is also a Senior Lecturer at Auckland University. Her research focuses on inherited eye disease as well as optic neuropathies.

Beyond the surface. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
A modern landmark glaucoma trial and first-of-its-kind that provides surprising and useful outcomes for current practice and research. Can the visual field be preserved with an intraocular-pressure-lowering drug in patients with open-angle glaucoma? Dr Jennifer Fan Gaskin explores Latanoprost for open-angle glaucoma.
View article here
Jennifer Fan Gaskin is a Consultant Ophthalmologist at the Royal Victorian Eye and Ear Hospital and a Principal Investigator at the Centre for Eye Research Australia where she leads Ocular Fibrosis Research. In 2021 she was named a Superstar of STEM by Science and Technology Australia. She is a Director of Australian Vision Research (formerly known as the Ophthalmic Research Institute of Australia) and a board member of the Australian and New Zealand Glaucoma Society.